If you have been reading about preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
==== Pit closures ==== Heseltine's responsibilities also included Energy, as the separate Energy ministry was abolished. Electricity companies now decided on their own contracts, rather than being obliged by the government to choose British coal. With plans being made for the privatisation of British Coal, on 13 October 1992 Heseltine and British Coal both separately announced that 31 of British Coal's 50 pits were to close, with the loss of 30,000 jobs. Most of the detailed work had been done by the minister of state Tim Eggar. Many of the mines in Nottinghamshire that had continued working during the 1984–1985 strike were to close. Although this policy was seen by the Nottinghamshire miners as a betrayal, there was hardly any organised resistance to the programme. The government stated that since the pits were losing money they could be sustained only through unjustifiable government subsidies. Mine supporters pointed to the mines' high productivity rates and to the fact that their monetary losses were due to the large subsidies that other European nations were giving to their coal industries. An early leak had seen little reaction but Heseltine was taken aback by the public anger. Over 100 pits had closed since the 1984–1985 strike. The closures were to be rushed because the Treasury, under pressure from Major, had agreed to make money for generous redundancy settlements available only in the 1992–1993 fiscal year.
There are a number of mechanisms through which religion may make a person happier, including social contact and support that result from religious pursuits, the mental activity that comes with optimism and volunteering, learned coping strategies that enhance one's ability to deal with stress, and psychological factors such as "reason for being." It may also be that religious people engage in behaviors related to good health, such as less substance abuse, since the use of psychotropic substances is sometimes considered abuse. The Handbook of Religion and Health describes a survey by Feigelman (1992) that examined happiness in Americans who have given up religion, in which it was found that there was little relationship between religious disaffiliation and unhappiness. A survey by Kosmin & Lachman (1993), also cited in this handbook, indicates that people with no religious affiliation appear to be at greater risk for depressive symptoms than those affiliated with a religion. A review of studies by 147 independent investigators found, "the correlation between religiousness and depressive symptoms was -.096, indicating that greater religiousness is mildly associated with fewer symptoms." The Legatum Prosperity Index reflects the repeated finding of research on the science of happiness that there is a positive link between religious engagement and well-being: people who report that God is very important in their lives are on average more satisfied with their lives, after accounting for their income, age and other individual characteristics.
=== Subdivisions === One recent classification recognised 297 species of clematis. Consequently, taxonomists and gardeners subdivide the genus. Several classification systems exist. Magnus Johnson divided Clematis into 19 sections, several with subsections. Christopher Grey-Wilson divided the genus into 9 subgenera (Clematis, Cheiropsis, Flammula, Archiclematis, Campanella, Atragene, Tubulosae, Pseudanemone, Viorna), several with sections and subsections within them. Several of the subdivisions are fairly consistent between these two systems; for example, all of Grey-Wilson's subgenera are used as sections by Johnson. Alternatively, John Howell defined twelve groups: the Evergreen, Alpina, Macropetala, Montana, Rockery, Early Large-Flowered, Late Large-Flowered, Herbaceous, Viticella, Texensis, Orientalis, and Late Mixed groups. Many of the most popular garden forms are cultivars belonging to the Viticella section of the subgenus Flammula as defined by Grey-Wilson. These larger-flowered cultivars are often used within garden designs to climb archways, pergolas, or wall-mounted trellises, or to grow through companion plants. These forms normally have large 12–15 cm diameter upward-facing flowers and are believed to involve crosses of C. patens, C. lanuginosa, and C. viticella. Early-season, large-flowering forms such as 'Nelly Moser' tend towards the natural flowering habit of C. patens or C. lanuginosa while later-flowering forms such as ×jackmanii are nearer in habit to C. viticella.
Beclabuvir, currently in clinical trials. Dasabuvir (Viekira Pak), non-nucleoside/nucleotide analog, approved by FDA in December 2014 (only in combination with ombitasvir, paritaprevir, and ritonavir). Deleobuvir, development terminated. Filibuvir, development terminated. Radalbuvir, currently in clinical trials. Setrobuvir, development terminated. Sofosbuvir (Sovaldi; Harvoni (combination with ledipasvir)): nucleotide analog, approved by the FDA in December 2013.
In the early years of using the technique, it was understood that it depended on the atmospheric 14C/12C ratio having remained the same over the preceding few thousand years. To verify the accuracy of the method, several artefacts that were datable by other techniques were tested; the results of the testing were in reasonable agreement with the true ages of the objects. Over time, however, discrepancies began to appear between the known chronology for the oldest Egyptian dynasties and the radiocarbon dates of Egyptian artefacts. Neither the pre-existing Egyptian chronology nor the new radiocarbon dating method could be assumed to be accurate, but a third possibility was that the 14C/12C ratio had changed over time. The question was resolved by the study of tree rings: comparison of overlapping series of tree rings allowed the construction of a continuous sequence of tree-ring data that spanned 8,000 years. (Since that time the tree-ring data series has been extended to 13,900 years.) In the 1960s, Hans Suess was able to use the tree-ring sequence to show that the dates derived from radiocarbon were consistent with the dates assigned by Egyptologists. This was possible because although annual plants, such as corn, have a 14C/12C ratio that reflects the atmospheric ratio at the time they were growing, trees only add material to their outermost tree ring in any given year, while the inner tree rings don't get their 14C replenished and instead start losing 14C through decay. Hence each ring preserves a record of the atmospheric 14C/12C ratio of the year it grew in.
Sources: en.wikipedia.org
Conveglipron (INNTooltip International Nonproprietary Name; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus. It is taken orally. The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals. Conveglipron is under development by Huadong Medicine in China. As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.
Long-term depression enacts mechanisms to decrease AMPA receptor density in selected dendritic spines, dependent on clathrin and calcineurin and distinct from that of constitutive AMPAR trafficking. The starting signal for AMPAR endocytosis is an NMDAR-dependent calcium influx from low-frequency stimulation, which in turn activates protein phosphatases PP1 and calcineurin. However, AMPAR endocytosis has also been activated by voltage-dependent calcium channels, agonism of AMPA receptors, and administration of insulin, suggesting general calcium influx as the cause of AMPAR endocytosis. Blockage of PP1 did not prevent AMPAR endocytosis, but antagonist application to calcineurin led to significant inhibition of this process. Calcineurin interacts with an endocytotic complex at the postsynaptic zone, explaining its effects on LTD. The complex, consisting of a clathrin-coated pit underneath a section of AMPAR-containing plasma membrane and interacting proteins, is the direct mechanism for reduction of AMPARs, in particular GluR2/GluR3 subunit-containing receptors, in the synapse. Interactions from calcineurin activate dynamin GTPase activity, allowing the clathrin pit to excise itself from the cell membrane and become a cytoplasmic vesicle. Once the clathrin coat detaches, other proteins can interact directly with the AMPARs using PDZ carboxyl tail domains; for example, glutamate receptor-interacting protein 1 (GRIP1) has been implicated in intracellular sequestration of AMPARs.
=== EC 2.8.4: Transferring alkylthio groups === EC 2.8.4.1: coenzyme-B sulfoethylthiotransferase EC 2.8.4.2: arsenate-mycothiol transferase EC 2.8.4.3: tRNA-2-methylthio-N6-dimethylallyladenosine synthase EC 2.8.4.4: [ribosomal protein S12] (aspartate89-C3)-methylthiotransferase EC 2.8.4.5: tRNA (N6-L-threonylcarbamoyladenosine37-C2)-methylthiotransferase
Because of this fact, it has become common practice to establish the quality of NMR ensembles, by comparing it against the unique conformation determined by X-ray diffraction, for the same protein. However, the X-ray diffraction structure may not exist, and, since the proteins in solution are flexible molecules, a protein represented by a single structure may lead to underestimate the intrinsic variation of the atomic positions of a protein. A set of conformations, determined by NMR or X-ray crystallography may be a better representation of the experimental data of a protein than a unique conformation. The utility of a model will be given, at least in part, by the degree of accuracy and precision of the model. An accurate model with relatively poor precision could be useful to study the evolutionary relationships between the structures of a set of proteins, whereas the rational drug design requires both precise and accurate models. A model that is not accurate, regardless of the degree of precision with which it was obtained will not be very useful. Since protein structures are experimental models that can contain errors, it is very important to be able to detect these errors. The process aimed at the detection of errors is known as validation. There are several methods to validate structures, some are statistical like PROCHECK and WHAT IF while others are based on physical principles as CheShift, or a mixture of statistical and physics principles PSVS.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.